Journey Medical Corporation (Nasdaq: DERM) announced its financial results for the full year ended December 31, 2025, revealing total revenues of $61.9 million, a 10% increase from $56.1 million in FY2024. The growth was primarily attributed to the successful launch of Emrosi™, which generated net revenues of $14.7 million after its introduction in early April 2025. The company reported approximately 53,000 prescriptions filled for Emrosi during the fiscal year, with payer access now available to over 100 million U.S. commercial lives. Despite the positive revenue growth, Journey Medical reported a net loss of $11.4 million, or $(0.47) per share, an improvement from a net loss of $14.7 million, or $(0.72) per share, in the previous year. The gross margin improved to 66.2%, up from 62.8% in FY2024, driven by higher-margin products and lower inventory costs. The company’s SG&A expenses increased by 10% to $44.4 million, reflecting operational activities related to Emrosi's launch. CEO Claude Maraoui expressed confidence in the company's strategy and the long-term potential of Emrosi as a key growth driver. The company plans to continue leveraging its commercial platform to enhance financial performance and advance innovative therapies for dermatological conditions.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.